Marama Labs has launched its CloudSpec instrument for nanomedicine development, which is expected to cut time and speed up ...

The composition of honey varies depending on the geographical and nectar sources of a region. The quality of honey depends on its physio-chemical and sensory properties ... The ulcerogenic agent, ...

obtained from the unit of toxicology and chemical safety, institute of bioengineering, University Miguel Hernández of Elche (Alicante) Spain. Hydrochloric acid (37%) was obtained from Merck KGaA ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee ...

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous challenges plaguing the company resulted in the dilution of the stock ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...